PeptiMimesis, a Strasbourg, France-based biopharma company, closed a €0.5m ($0.6m) first tranche of a €1.2m ($1.4m) funding round.
The investment was made by Cap Innov’Est, a regionally-based seed fund.
The company will use the funds to initiate its research activities on the design and characterization of transmembrane peptides.
Created in October 2015 and led by president Marjorie Sidhoum, PeptiMimesis is a biopharmaceutical company dedicated to the discovery and development of transmembrane therapeutic peptides. The company’s proprietary platform aims to deliver a set of drug candidates that act on validated targets in the field of immuno-oncology, oncology and immune diseases.
FinSMEs
20/04/2016